Welcome to our dedicated page for Corbus Pharmaceu news (Ticker: CRBP), a resource for investors and traders seeking the latest updates and insights on Corbus Pharmaceu stock.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage biopharmaceutical company advancing targeted therapies in precision oncology and metabolic disorders. This page serves as the definitive source for CRBP news, offering investors and researchers timely updates on scientific advancements and corporate developments.
Access verified information on clinical trial progress, regulatory milestones, and strategic partnerships across CRBP's pipeline. Key focus areas include Nectin-4 targeting antibody-drug conjugates, TGFβ pathway inhibitors, and novel obesity treatments designed to address critical unmet medical needs.
Our curated news collection enables efficient tracking of CRBP's innovative approaches to drug development. Stay informed about emerging data from studies evaluating CRB-701 in solid tumors, CRB-601's impact on tumor microenvironments, and CRB-913's potential in weight management.
Bookmark this page for direct access to official press releases and third-party analyses. Regular updates ensure you maintain current awareness of CRBP's position at the forefront of precision medicine development.
Corbus Pharmaceuticals (NASDAQ: CRBP) has announced its participation in the 7th Annual Evercore HealthCONx Conference, scheduled for December 3-5, 2024, in Coral Gables, FL. CEO Yuval Cohen, Ph.D., will engage in a fireside chat and conduct one-on-one investor meetings during the event. The fireside chat is specifically scheduled for December 3, 2024, at 4:15 p.m. ET, with a webcast available for viewing.
Corbus Pharmaceuticals (NASDAQ: CRBP) has announced its participation in the upcoming Jefferies London Healthcare Conference, scheduled for November 19-21, 2024, in London, UK. The company's CEO, Yuval Cohen, Ph.D., will engage in a fireside chat and conduct one-on-one investor meetings during the event. The fireside chat is specifically scheduled for November 19, 2024, at 10:30 a.m. GMT, with a webcast link provided for interested parties.
Corbus Pharmaceuticals reported Q3 2024 financial results and corporate updates. The company completed enrollment for the dose escalation part of its Phase 1 trial for CRB-701, with first data expected in Q1 2025. New pre-clinical data for CRB-913 was presented at Obesity Week 2024, with Phase 1 trial expected to start in Q1 2025. The company reported a net loss of $13.8 million, or $1.15 per share. Operating expenses increased to $15.5 million. Cash position stands at $159.4 million, expected to fund operations through Q3 2027. The company raised $35.6 million through ATM program and paid off an $11.8 million loan.
Corbus Pharmaceuticals (NASDAQ: CRBP) presented new pre-clinical data for CRB-913, its CB1 inverse agonist, at Obesity Week 2024. Key findings show CRB-913's brain levels are 15-fold lower than monlunabant, with a 10 times higher plasma-to-brain ratio. The compound demonstrated significant weight loss of up to 38% in DIO mice at doses ranging from 5 to 80 mg/kg/day. Notably, when replacing semaglutide treatment, CRB-913 maintained weight loss and doubled fat reduction compared to semaglutide maintenance. The company plans to begin Phase 1 clinical trials in Q1 2025.
Corbus Pharmaceuticals (NASDAQ: CRBP) has announced its participation in the upcoming Guggenheim Securities Healthcare Innovation Conference in Boston, MA. The company's CEO, Yuval Cohen, Ph.D., will engage in a fireside chat and conduct one-on-one investor meetings during the event, which runs from November 11-13, 2024. Dr. Cohen's fireside chat is scheduled for November 12, 2024, at 10:00 a.m. ET, and will be available via webcast.
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) has announced its participation in the BMO Capital Markets' Oncology Summit on October 8, 2024, in New York, NY. The company's Chief Medical Officer, Dr. Dominic Smethurst, will be part of a panel discussion titled 'Capitalizing on Validated Mechanism in Oncology' at 1:30 pm ET.
Additionally, Dr. Smethurst and Yuval Cohen, Ph.D., the Chief Executive Officer of Corbus, will be available for one-on-one investor meetings during the event. Interested parties are advised to contact their BMO Capital Markets sales representative for registration details.
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) has announced its participation in the 2024 Cantor Global Health Conference, scheduled for September 17-19, 2024, in New York City. The company's CEO, Yuval Cohen, Ph.D., will be presenting at the event.
Key details of the presentation include:
- Date: September 17, 2024
- Time: 8:00 AM Eastern Time
- Location: InterContinental New York Barclay Hotel
- Format: Fireside chat with Cantor analyst Prakhar Agrawal
Dr. Cohen will also be available for one-on-one investor meetings during the conference. A webcast link for the presentation has been provided for those unable to attend in person.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has appointed Winston Kung to its Board of Directors, effective August 16, 2024. Mr. Kung, who will also chair the Audit Committee, brings over 20 years of leadership experience in life sciences and investment banking. Currently serving as CFO of Arrivent BioPharma, he has held senior positions at PMV Pharmaceuticals, Celgene, Citigroup, Lehman Brothers, Genentech, and Amgen.
The company's leadership expressed enthusiasm for Mr. Kung's expertise in pharma industry and capital markets, viewing his appointment as valuable for advancing Corbus' pipeline. Simultaneously, Avery "Chip" Catlin has resigned from the Board and as Audit Committee Chair after serving for over ten years.
Corbus Pharmaceuticals (NASDAQ: CRBP) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
1. CRB-701: Encouraging Phase 1 data presented at ASCO 2024, showing 44% ORR in metastatic urothelial cancer and 43% ORR in cervical cancer. Phase 1 dose escalation underway in USA and Europe.
2. CRB-913: Phase 1 study for obesity treatment expected to commence in Q1 2025.
3. CRB-601: FDA cleared IND, Phase 1 study expected to initiate in Q4 2024.
4. Financial Results: Net loss of $10.0 million for Q2 2024. Cash, cash equivalents, and investments of $147 million as of June 30, 2024, expected to fund operations through Q3 2027.
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) has announced its participation in two upcoming investor conferences in August 2024. CEO Yuval Cohen, Ph.D., will provide corporate updates and engage in investor meetings at these events:
1. BTIG Virtual Biotechnology Conference (August 5-6, 2024): Invitation-only, one-on-one investor meetings.
2. Wedbush PacGrow Healthcare Conference (August 13-14, 2024): Invitation-only, one-on-one and small group investor meetings.
Interested investors should contact their respective BTIG or Wedbush representatives to arrange meetings with Corbus management during these conferences.
